2'3'-cGAMP (sodium salt): High-Affinity STING Agonist for Innate Immunity Research

Executive Summary: 2'3'-cGAMP (sodium salt) is an endogenous cyclic dinucleotide second messenger that directly activates the STING pathway and robustly induces type I interferon signaling (ABCC10-mediated cGAMP efflux drives cancer cell radiotherapy resistance, https://doi.org/10.1038/s41418-025-01552-1). With a binding affinity (Kd) of 3.79 nM for STING, it surpasses other cyclic dinucleotides in potency ([APExBIO product page](https://www.apexbt.com/2-3-cgamp-sodium-salt.html)). The compound is water-soluble (≥7.56 mg/mL), chemically stable at -20°C, and has defined parameters for research workflows. Recent studies confirm its value in modeling radiotherapy resistance mechanisms, immune checkpoint modulation, and the paracrine activation of immune cells in the tumor microenvironment (DOI). 2'3'-cGAMP (sodium salt) from APExBIO is the research standard for functional assays targeting the cGAS-STING axis.

Biological Rationale

2'3'-cGAMP is a cyclic dinucleotide generated by cyclic GMP-AMP synthase (cGAS) upon sensing cytosolic double-stranded DNA (dsDNA) [1]. It serves as a second messenger, transmitting signals that activate the stimulator of interferon genes (STING) protein. STING activation leads to phosphorylation of TBK1 and IRF3, culminating in the transcription of type I interferon genes, notably IFN-β. This pathway is central to the innate immune response against viral infection, tumorigenesis, and cellular stress. 2'3'-cGAMP-mediated STING signaling can both promote antitumor immunity and, paradoxically, contribute to radiotherapy resistance through modulation of the tumor microenvironment and immune cell recruitment [1].

Mechanism of Action of 2'3'-cGAMP (sodium salt)

2'3'-cGAMP (sodium salt) is a research-grade, synthetic analog that mimics endogenous 2'3'-cGAMP in structure and function. Upon introduction into mammalian cells, it binds directly to human STING with a dissociation constant (Kd) of 3.79 nM, enabling robust and specific pathway activation [APExBIO]. This interaction triggers STING translocation from the endoplasmic reticulum to perinuclear compartments, recruitment and activation of TBK1, and phosphorylation of IRF3. Phosphorylated IRF3 drives the transcription of type I interferons and other cytokines. The sodium salt form ensures water solubility (≥7.56 mg/mL) and experimental reproducibility. The compound is insoluble in ethanol and DMSO, which is critical for protocol planning [APExBIO].

Evidence & Benchmarks

• 2'3'-cGAMP (sodium salt) directly activates human STING with a Kd of 3.79 nM, outperforming other cyclic dinucleotides (APExBIO, product page).
• In irradiated cancer cells, 2'3'-cGAMP is exported via ABCC10, attenuating STING-TBK1-IRF3 signaling and contributing to radiotherapy resistance (Zhang et al. 2025).
• Extracellular 2'3'-cGAMP can activate STING in bystander cells, amplifying antitumor immunity through paracrine signaling (Zhang et al. 2025).
• 2'3'-cGAMP (sodium salt) is stable at -20°C for extended periods and maintains bioactivity after repeated freeze-thaw cycles (APExBIO, product page).
• In cell-based assays, the compound reliably induces IFN-β and ISG expression, making it suitable for immune checkpoint and antiviral research (yt-broth-2x-liquid.com).

Applications, Limits & Misconceptions

2'3'-cGAMP (sodium salt) is used in immunology, inflammation, antiviral, and cancer biology research. It is central to studies dissecting the cGAS-STING pathway, immune checkpoint modulation, and innate immune-based therapeutic development. The compound enables mechanistic dissection in both cancer and infectious disease models.

Common Pitfalls or Misconceptions

• 2'3'-cGAMP (sodium salt) is not intended for diagnostic or clinical use; it is strictly for research applications (APExBIO, product page).
• The compound is insoluble in DMSO or ethanol, which may impede workflows using these solvents.
• Exogenous 2'3'-cGAMP does not activate pathways in cells lacking functional STING protein.
• Not all observed STING pathway effects are beneficial; STING activation can sometimes promote immunosuppression or tumor progression, depending on context (Zhang et al. 2025).
• High concentrations may induce cytotoxicity in some cell types; titration is required for each assay system.

This article extends prior coverage by clarifying the quantitative benchmarks and mechanistic context for using 2'3'-cGAMP (sodium salt) in radiotherapy resistance models, updating the broader translational landscape presented in 2'3'-cGAMP (Sodium Salt): Translating cGAS-STING Mechanisms. In contrast to 'Benchmark STING Agonist for Innate Immunity', this review details recent peer-reviewed findings on ABCC10-mediated cGAMP export and its implications for radiotherapy outcomes. For detailed guidance on cell assay design, see 'Optimizing Cell Assays with 2'3'-cGAMP (sodium salt)', whereas this article provides a systemic overview and mechanistic update.

Workflow Integration & Parameters

• Solubility: Water-soluble at ≥7.56 mg/mL. Insoluble in DMSO and ethanol (APExBIO).
• Storage: Stable at -20°C; avoid repeated freeze-thaw cycles for maximal activity.
• Concentration Ranges: Effective in vitro at 0.1–10 μM; titrate for specific cell lines and readouts.
• Controls: Always include STING-deficient or pathway-inhibited controls to verify specificity.
• Assay Compatibility: Suitable for cell-based, biochemical, and in vivo models. Not compatible with some organic solvents.

For scenario-driven cell assay guidance, see this workflow article.

Conclusion & Outlook

2'3'-cGAMP (sodium salt) from APExBIO is a validated, high-affinity STING agonist for dissecting innate immune signaling and modeling cancer immunotherapy, radiotherapy resistance, and antiviral responses. Its defined chemical and biophysical parameters make it indispensable for reproducible research in immunology and translational medicine. Continued mechanistic studies—especially those clarifying ABCC10- and microenvironment-mediated cGAMP dynamics—will refine its application in next-generation immunotherapies (Zhang et al. 2025).